Thiazolidinediones as anti-cancer agents.
Publication/Presentation Date
1-1-2008
Abstract
The PPAR-gamma (PPAR-γ) activating thiazolidinedione (TZD) medications are a class of drugs used to improve lipid and glucose metabolism in type-2 diabetes. In addition to their known insulin sensitization action, these drugs have been shown to suppress tumor development in several in vitro and in vivo models. Among the proposed mechanisms for the anti-tumor effects of TZDs, apoptosis induction, cell cycle arrest, and differentiation have been extensively reported. Interestingly, some of the observed anti-tumor effects are independent of PPAR-γ activation. The following review will discuss studies employing TZDs as anti-cancer therapies for the most common types of cancers including, lung, breast, and colon and will explore the principal PPAR-γ-dependent and -independent mechanisms by which TZDs exert their anti-tumor effects.
Volume
6
Issue
A
First Page
25
Last Page
34
ISSN
1543-9135
Published In/Presented At
Blanquicett, C., Roman, J., & Hart, C. M. (2008). Thiazolidinediones as anti-cancer agents. Cancer therapy, 6(A), 25–34.
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
19079765
Department(s)
Administration and Leadership
Document Type
Article